Tahereh Safari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tahereh Safari has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Mehdi Nematbakhsh
Water and Electrolytes Research Center, Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran
18 shared publications - Ardeshir Talebi
Department of Pathology, Medical School, Dental Research Center, Dental Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
10 shared publications Zahra Pezeshki
Isfahan Univ Med Sci, Water & Electrolytes Res Ctr, Esfahan, Iran
10 shared publications- Hamid Nasri
Department of Natural Sciences, The University of Georgia, Tbilisi, Georgia
9 shared publications - Farzaneh Ashrafi
Water & Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
8 shared publications Fatemeh Eshraghi-Jazi
Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
8 shared publications
Latest Publications
- 1 December 2021
- Published by Bentham Science Publishers Ltd. in Current Hypertension Reviews
- Vol. 17 (3) , 207-216
Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
The new pandemic Coronavirus Disease 2019 (COVID-19) causes a wide range of clinical consequences, from asymptomatic infection to acute respiratory failure, and it is very heterogeneous. The renin-angiotensin system (RAS) is well recognized as a key regulating system in circulatory homeostasis that plays prominent roles in pathophysiological processes in abnormal activation, for instance, renal and cardiovascular diseases, obesity, and stroke. Angiotensin-converting enzyme 2(ACE2) is a component of the RAS system. However, unlike the ACE, its activity is not inhibited by the ACE inhibitors. The major product of ACE2 is Ang1-7, known as a vasodilator peptide and part of the depressant arm of the RAS. There are two forms of ACE2; Transmembrane ACE2 and soluble ACE2. Coronavirus is covered with some proteins in order to help viral attachment to the cell membrane ACE2 as a receptor and then fuse and enter the cells. ACE2 was expressed in the oral cavity, salivary glands of the mouth, esophagus, myocardial cells, kidney, and enterocytes, along with all the respiratory tract, intestine, and blood vessels. In this article, the renin- angiotensin system and its components have been explained. Moreover, the organs involved in COVID-19 disease, and the possible causes of damage to these organs have also been discussed. The probable mechanism of using ACE2 in viral attachment and the probable treatment processes will also be reviewed based on the surface proteins of the virus and ACE2. In addition, we briefly discuss anti-angiotensin drugs and why patients with chronic diseases are more susceptible to COVID-19 infection and show worse progression.
- 1 December 2021
- Published by Bentham Science Publishers Ltd. in Current Hypertension Reviews
- Vol. 17 (3) , 207-216
Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
The new pandemic Coronavirus Disease 2019 (COVID-19) causes a wide range of clinical consequences, from asymptomatic infection to acute respiratory failure, and it is very heterogeneous. The renin-angiotensin system (RAS) is well recognized as a key regulating system in circulatory homeostasis that plays prominent roles in pathophysiological processes in abnormal activation, for instance, renal and cardiovascular diseases, obesity, and stroke. Angiotensin-converting enzyme 2(ACE2) is a component of the RAS system. However, unlike the ACE, its activity is not inhibited by the ACE inhibitors. The major product of ACE2 is Ang1-7, known as a vasodilator peptide and part of the depressant arm of the RAS. There are two forms of ACE2; Transmembrane ACE2 and soluble ACE2. Coronavirus is covered with some proteins in order to help viral attachment to the cell membrane ACE2 as a receptor and then fuse and enter the cells. ACE2 was expressed in the oral cavity, salivary glands of the mouth, esophagus, myocardial cells, kidney, and enterocytes, along with all the respiratory tract, intestine, and blood vessels. In this article, the renin- angiotensin system and its components have been explained. Moreover, the organs involved in COVID-19 disease, and the possible causes of damage to these organs have also been discussed. The probable mechanism of using ACE2 in viral attachment and the probable treatment processes will also be reviewed based on the surface proteins of the virus and ACE2. In addition, we briefly discuss anti-angiotensin drugs and why patients with chronic diseases are more susceptible to COVID-19 infection and show worse progression.
- Open Access
- 15 November 2020
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 93 (4) , e12999
Gastrointestinal and renal complications in SARS‐CoV‐2‐infected patients: Role of immune system
The recent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) disease has been accompanied by various gastrointestinal (GI) and renal manifestations in significant portion of infected patients. Beside studies on the respiratory complications of coronavirus infection, understanding the essential immunological processes underlying the different clinical manifestations of virus infection is crucial for the identification and development of effective therapies. In addition to the respiratory tract, the digestive and urinary systems are the major sources of virus transmission. Thus, knowledge about the invasion mechanisms of SARS‐CoV‐2 in these systems and the immune system responses is important for implementing the infection prevention strategies. This article presents an overview of the gut and renal complications in SARS‐CoV‐2 infection. We focus on how SARS‐CoV‐2 interacts with the immune system and the consequent contribution of immune system, gut, and renal dysfunctions in the development of disease.
- 15 November 2020
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 93 (4) , e12999
Open AccessGastrointestinal and renal complications in SARS‐CoV‐2‐infected patients: Role of immune system
The recent severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) disease has been accompanied by various gastrointestinal (GI) and renal manifestations in significant portion of infected patients. Beside studies on the respiratory complications of coronavirus infection, understanding the essential immunological processes underlying the different clinical manifestations of virus infection is crucial for the identification and development of effective therapies. In addition to the respiratory tract, the digestive and urinary systems are the major sources of virus transmission. Thus, knowledge about the invasion mechanisms of SARS‐CoV‐2 in these systems and the immune system responses is important for implementing the infection prevention strategies. This article presents an overview of the gut and renal complications in SARS‐CoV‐2 infection. We focus on how SARS‐CoV‐2 interacts with the immune system and the consequent contribution of immune system, gut, and renal dysfunctions in the development of disease.
- Open Access
- 8 October 2020
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 11 (1) , e4
The protective effects of eugenol on metabolic-syndrome, renal damages
Introduction: Metabolic syndrome consists of a group of abnormities which is involved with chronic kidney disease and nephropathy. Eugenol is an important phenolic component, which is present in many plants’ essential oils such as cloves oil with antioxidant effects. Objectives: Our study planned to demonstrate eugenol’s effects over nephrotoxicity derived from metabolic syndrome. Materials and Methods: Thirty-five male Wistar rats were picked accidentally and then divided into five groups including 1) tap water; 2) water with fructose10%; 3) water with fructose + sweet almond oil and administered intraperitoneally; 4) water with fructose+ eugenol 50 mg/kg/d and administered intraperitoneally; 5) water with fructose+ eugenol 100 mg/kg/d administered intraperitoneally. This regime lasted for 60 days, and at the beginning of day 31st, injections started for 30 days. Assessment of serum, urine and renal parameters (in homogenized kidney tissue) were conducted in the last step. Results: The results argued that the induction of metabolic syndrome following renal injury has significantly increased serum blood urea nitrogen (BUN) and creatinine (Cr) levels in the fructose group. Consumption of eugenol resulted in a significant reduction in the level of these two biochemical factors (P < 0.05). The renal level of malondialdehyde (MDA) increased in the fructose group while treatment with a dose of 50 eugenol decreasing its level (P < 0.05). Proteinuria and kidney tissue damage score (KTDS) increased in the fructose group compared with the tap water group (P < 0.001). It is noteworthy that treatment with eugenol did not affect the level of proteinuria and KTDS with any of the used doses. Conclusion: Our results indicated the improvement of renal functioning and decrease in lipid peroxidation, although eugenol doses used in this study did not reduce proteinuria and KTDS.
- 8 October 2020
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 11 (1) , e4
Open AccessThe protective effects of eugenol on metabolic-syndrome, renal damages
Introduction: Metabolic syndrome consists of a group of abnormities which is involved with chronic kidney disease and nephropathy. Eugenol is an important phenolic component, which is present in many plants’ essential oils such as cloves oil with antioxidant effects. Objectives: Our study planned to demonstrate eugenol’s effects over nephrotoxicity derived from metabolic syndrome. Materials and Methods: Thirty-five male Wistar rats were picked accidentally and then divided into five groups including 1) tap water; 2) water with fructose10%; 3) water with fructose + sweet almond oil and administered intraperitoneally; 4) water with fructose+ eugenol 50 mg/kg/d and administered intraperitoneally; 5) water with fructose+ eugenol 100 mg/kg/d administered intraperitoneally. This regime lasted for 60 days, and at the beginning of day 31st, injections started for 30 days. Assessment of serum, urine and renal parameters (in homogenized kidney tissue) were conducted in the last step. Results: The results argued that the induction of metabolic syndrome following renal injury has significantly increased serum blood urea nitrogen (BUN) and creatinine (Cr) levels in the fructose group. Consumption of eugenol resulted in a significant reduction in the level of these two biochemical factors (P < 0.05). The renal level of malondialdehyde (MDA) increased in the fructose group while treatment with a dose of 50 eugenol decreasing its level (P < 0.05). Proteinuria and kidney tissue damage score (KTDS) increased in the fructose group compared with the tap water group (P < 0.001). It is noteworthy that treatment with eugenol did not affect the level of proteinuria and KTDS with any of the used doses. Conclusion: Our results indicated the improvement of renal functioning and decrease in lipid peroxidation, although eugenol doses used in this study did not reduce proteinuria and KTDS.
- Open Access
- 29 May 2020
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 9 (4) , e29
Does exercise training attenuate cisplatin nephrotoxicity?
Cisplatin (CP), a medication originating from the platinum has been used for solid cancers’ treatment in the last decade. CP is associated with numerous side effects as well. One of the side effects is nephrotoxicity. There are some types of procedure which can attenuate harmful effects of the drug, and the effectiveness of physical activity has been a controversial topic. It is well established that physical activity has positive effects on chronic kidney disease (CKD). The exercise training can modulate CP induced muscle wasting both in males and females. Although exercise training may have protective effect on renal function and the related risk factors, it cannot attenuate the renal injury resulted from CP therapy in females. The exercise training may improve interleukin 6 and heme oxygenase-1, reduces the production of CD4+T cell cytokines from the kidney, which play a major role in adaptive immune response. The present mini-review considered the effect of exercise training accompanied by the CP treatment.
- 29 May 2020
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 9 (4) , e29
Open AccessDoes exercise training attenuate cisplatin nephrotoxicity?
Cisplatin (CP), a medication originating from the platinum has been used for solid cancers’ treatment in the last decade. CP is associated with numerous side effects as well. One of the side effects is nephrotoxicity. There are some types of procedure which can attenuate harmful effects of the drug, and the effectiveness of physical activity has been a controversial topic. It is well established that physical activity has positive effects on chronic kidney disease (CKD). The exercise training can modulate CP induced muscle wasting both in males and females. Although exercise training may have protective effect on renal function and the related risk factors, it cannot attenuate the renal injury resulted from CP therapy in females. The exercise training may improve interleukin 6 and heme oxygenase-1, reduces the production of CD4+T cell cytokines from the kidney, which play a major role in adaptive immune response. The present mini-review considered the effect of exercise training accompanied by the CP treatment.
- Open Access
- 1 January 2019
- Published by Wolters Kluwer Health in International Journal of Preventive Medicine
- Vol. 10 (1) , 151
Effects of Eugenol on Pain Response to the Formalin Test and Plasma Antioxidant Activity in High Fructose Drinking Water in Male Rats
Background: Increased consumption of fructose in recent years has increased the risk of developing metabolic syndrome. In this syndrome, induction of oxidative stress, cellular dysfunction, and decrease of antioxidant capacity can change response to pain. Therefore, this study aims to investigate the antinociceptive and antioxidant effects of eugenol on metabolic syndrome induced by a fructose-rich diet in rats. Methods: The rats were randomly assigned to five groups, to be under experiment for eight weeks. The first, control group, the second fructose 10% plus tween 0.5% (Fr + veh), the third fructose 10% (Fr), and the fourth fructose 10% plus a single dose of eugenol 100 mg/kg (Fr + EoS). However, the fifth obtained fructose 10% plus a continuous dose of eugenol 20 mg/kg/day (Fr + EoC) for the last 10 days of the experiment. After formalin test, blood samples were taken from the animals’ hearts followed by analysis for biochemical factors. Results: This study shows that fructose administration does not change any pain response and there are not any changes in pain response between Fr group and control group. However, treatment with single and continuous dose of eugenol in Fr + EoS and Fr + EoC groups significantly decreases response to pain in the first and second phase of formalin test in comparison with Fr group (P<0.05). Continuous does of eugenol improved serum malondialdehyde and total antioxidant capacity levels in Fr + Eoc group in comparison with Fr group. Conclusions: In the present work, new findings suggest the beneficial effects of eugenol in pain relief, improved serum glucose, insulin levels, and improved antioxidant activity in metabolic syndrome.
- 1 January 2019
- Published by Wolters Kluwer Health in International Journal of Preventive Medicine
- Vol. 10 (1) , 151
Open AccessEffects of Eugenol on Pain Response to the Formalin Test and Plasma Antioxidant Activity in High Fructose Drinking Water in Male Rats
Background: Increased consumption of fructose in recent years has increased the risk of developing metabolic syndrome. In this syndrome, induction of oxidative stress, cellular dysfunction, and decrease of antioxidant capacity can change response to pain. Therefore, this study aims to investigate the antinociceptive and antioxidant effects of eugenol on metabolic syndrome induced by a fructose-rich diet in rats. Methods: The rats were randomly assigned to five groups, to be under experiment for eight weeks. The first, control group, the second fructose 10% plus tween 0.5% (Fr + veh), the third fructose 10% (Fr), and the fourth fructose 10% plus a single dose of eugenol 100 mg/kg (Fr + EoS). However, the fifth obtained fructose 10% plus a continuous dose of eugenol 20 mg/kg/day (Fr + EoC) for the last 10 days of the experiment. After formalin test, blood samples were taken from the animals’ hearts followed by analysis for biochemical factors. Results: This study shows that fructose administration does not change any pain response and there are not any changes in pain response between Fr group and control group. However, treatment with single and continuous dose of eugenol in Fr + EoS and Fr + EoC groups significantly decreases response to pain in the first and second phase of formalin test in comparison with Fr group (P<0.05). Continuous does of eugenol improved serum malondialdehyde and total antioxidant capacity levels in Fr + Eoc group in comparison with Fr group. Conclusions: In the present work, new findings suggest the beneficial effects of eugenol in pain relief, improved serum glucose, insulin levels, and improved antioxidant activity in metabolic syndrome.
- Open Access
- 1 January 2019
- Published by Medknow in Research in Pharmaceutical Sciences
- Vol. 14 (5) , 441-447
The effect of angiotensin 1-7 and losartan on renal ischemic/reperfusion injury in male rats
Ischemia/reperfusion (I/R) is a major cause of acute kidney injury. Several studies have shown that renin angiotensin (Ang) system and activation of Ang II type 1 receptor (AT1) are involved in various forms of kidney diseases. Likewise, Ang 1-7 as a physiologic antagonist of AT1 and losartan could possibly protect the kidney against I/R damage. Therefore, we investigated renal injury by administering the drugs before and after I/R. Fifty-four male Wistar rats were randomly assigned to five groups as follows. 1, Sham operated; 2, saline group (as a control group); 3, losartan group; 4, Ang 1-7group; and 5, Ang 1-7 + losartan simultaneously. It should be noted that groups 2-5 consisted of two separate I/R-induced subgroups both receiving medication where the first groups received the treatment 15 min before induction of I/R while the medications were given to the second groups immediately after induction of I/R. Twenty four h after I/R, blood samples were collected, and then levels of serum urea nitrogen (BUN), creatinine (Cr), nitrite, malondialdehyde (MDA), lactate dehydrogenase (LDH) and total antioxidant capacity (TAC) were measured. Likewise, nitrite, MDA and TAC were measured in the homogenized kidney tissues. After the induction of I/R, the BUN, Cr, LDH, and kidney tissue damage score increased. Administration of Ang 1-7 alone or simultaneously with losartan decreased the levels of aforementioned factors. Also, kidney MDA and nitrate levels significantly increased after I/R induction (P < 0.05). According to the results of this study, it can be claimed that the effect of losartan in the presence of Mas receptor is statistically significant and kidney damage dramatically decreases.
- 1 January 2019
- Published by Medknow in Research in Pharmaceutical Sciences
- Vol. 14 (5) , 441-447
Open AccessThe effect of angiotensin 1-7 and losartan on renal ischemic/reperfusion injury in male rats
Ischemia/reperfusion (I/R) is a major cause of acute kidney injury. Several studies have shown that renin angiotensin (Ang) system and activation of Ang II type 1 receptor (AT1) are involved in various forms of kidney diseases. Likewise, Ang 1-7 as a physiologic antagonist of AT1 and losartan could possibly protect the kidney against I/R damage. Therefore, we investigated renal injury by administering the drugs before and after I/R. Fifty-four male Wistar rats were randomly assigned to five groups as follows. 1, Sham operated; 2, saline group (as a control group); 3, losartan group; 4, Ang 1-7group; and 5, Ang 1-7 + losartan simultaneously. It should be noted that groups 2-5 consisted of two separate I/R-induced subgroups both receiving medication where the first groups received the treatment 15 min before induction of I/R while the medications were given to the second groups immediately after induction of I/R. Twenty four h after I/R, blood samples were collected, and then levels of serum urea nitrogen (BUN), creatinine (Cr), nitrite, malondialdehyde (MDA), lactate dehydrogenase (LDH) and total antioxidant capacity (TAC) were measured. Likewise, nitrite, MDA and TAC were measured in the homogenized kidney tissues. After the induction of I/R, the BUN, Cr, LDH, and kidney tissue damage score increased. Administration of Ang 1-7 alone or simultaneously with losartan decreased the levels of aforementioned factors. Also, kidney MDA and nitrate levels significantly increased after I/R induction (P < 0.05). According to the results of this study, it can be claimed that the effect of losartan in the presence of Mas receptor is statistically significant and kidney damage dramatically decreases.
- Open Access
- 20 August 2018
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 8 (2) , 16
Losartan and magnesium sulfate administration reduce gentamicin-induced nephrotoxicity in rat model
Background: Nephrotoxicity is the most known side effect of gentamicin. In addition, renin angiotensin system (RAS) plays an important role in the pathogenesis of renal injury and nephrotoxicity. Hypomagnesaemia is other complication of gentamicin. Previous studies reported that magnesium plays an important role in cell enzymatic functions, reducing lipid peroxidation. Objectives: We investigated the role of losartan and magnesium sulfate (MgSO4 ) on gentamicin nephrotoxicity. Materials and Methods: In this study, rats randomly assigned to five groups. The first group, received saline, the second group received gentamicin 80 mg/kg/d, intraperitoneally (ip), and the third group, received a regular dose of losartan, 10 mg/kg/d + gentamicin 80 mg/kg/d. The fourth group received MgSO4 , 80 mg/kg/d + gentamicin 80 mg/kg/d. The fifth group obtained a continuous dose of gentamicin 80 mg/kg/d + losartan 10 mg/kg/d + MgSO4 80 mg/kg/d simultaneously. Nine days after administration of drugs, blood samples were collected from the heart. The level of urea, creatinine (Cr), malondialdehyde (MDA) and nitrite were measured in the animal serum and homogenized kidney tissue. Results: Gentamicin increased serum urea and Cr levels. The administration of losartan and MgSO4 lonely and combination of them, significantly reduced the levels of serum urea and Cr. Losartan alone and combination of losartan and MgSO4 compared with gentamicin, significantly decreased kidney MDA level too. Decrease of kidney nitrite level by gentamicin was compensated by the administration of losartan, MgSO4 alone or their combination. Additionally, losartan and MgSO4 alone and their combination together significantly reduced renal damage. Conclusions: The results of this study indicated that administration of losartan and MgSO4 individually and their combination decreased kidney nephrotoxicity and improved renal function. This effect is probably related to the improvement of antioxidant status and renal blood flow.
- 20 August 2018
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 8 (2) , 16
Open AccessLosartan and magnesium sulfate administration reduce gentamicin-induced nephrotoxicity in rat model
Background: Nephrotoxicity is the most known side effect of gentamicin. In addition, renin angiotensin system (RAS) plays an important role in the pathogenesis of renal injury and nephrotoxicity. Hypomagnesaemia is other complication of gentamicin. Previous studies reported that magnesium plays an important role in cell enzymatic functions, reducing lipid peroxidation. Objectives: We investigated the role of losartan and magnesium sulfate (MgSO4 ) on gentamicin nephrotoxicity. Materials and Methods: In this study, rats randomly assigned to five groups. The first group, received saline, the second group received gentamicin 80 mg/kg/d, intraperitoneally (ip), and the third group, received a regular dose of losartan, 10 mg/kg/d + gentamicin 80 mg/kg/d. The fourth group received MgSO4 , 80 mg/kg/d + gentamicin 80 mg/kg/d. The fifth group obtained a continuous dose of gentamicin 80 mg/kg/d + losartan 10 mg/kg/d + MgSO4 80 mg/kg/d simultaneously. Nine days after administration of drugs, blood samples were collected from the heart. The level of urea, creatinine (Cr), malondialdehyde (MDA) and nitrite were measured in the animal serum and homogenized kidney tissue. Results: Gentamicin increased serum urea and Cr levels. The administration of losartan and MgSO4 lonely and combination of them, significantly reduced the levels of serum urea and Cr. Losartan alone and combination of losartan and MgSO4 compared with gentamicin, significantly decreased kidney MDA level too. Decrease of kidney nitrite level by gentamicin was compensated by the administration of losartan, MgSO4 alone or their combination. Additionally, losartan and MgSO4 alone and their combination together significantly reduced renal damage. Conclusions: The results of this study indicated that administration of losartan and MgSO4 individually and their combination decreased kidney nephrotoxicity and improved renal function. This effect is probably related to the improvement of antioxidant status and renal blood flow.
- Open Access
- 1 January 2018
- Published by Medknow in International Journal of Preventive Medicine
- Vol. 9 (1) , 108
Sex difference in gentamicin-induced nephrotoxicity: Influence of L-arginine in rat model
Background: L-arginine is an important precursor for the formation of nitric oxide (NO). According to previous studies, NO function is related to gender. Likewise, chronic renal diseases have lower prevalence in female. Gentamicin (GM) is an aminoglycoside antibiotic. According to some studies, males are more sensitive to GM renal nephrotoxicity. This study attempts to find protective effects of L-arginine on GM nephrotoxicity in male and female rats. Methods: Male and female rats were divided into eight groups: Rats were randomly assigned to 8 groups each including both male and female rats. The first and second groups received vehicle (saline), the third and fourth groups received gentamicin (80 mg/kg), the fifth and sixth groups received L-arginine (150 mg/kg), and finally, seventh and eighth groups received gentamicin+ L- arginine. Next, 9 days after administering drugs, blood samples were collected from the heart. After making sacrifices, the level of blood urea, creatinine (Cr), nitrite, and malondialdehyde (MDA) was measured in serums. Likewise, nitrite and MDA were measured in the homogenized kidney tissue. Results: GM significantly increased serum level of urea and Cr in male and female rats (P < 0.05). However, co-administration of GM + L-arginine significantly did not decrease urea and Cr level in male rats, whereas, in female rats, they significantly reduced (P < 0.05). In response to GM, renal MDA level increased in male and female rats (P < 0.05), and in the presence of GM + L-arginine, the level of MDA significantly decreased in both genders (P < 0.05). Conclusions: L-arginine demonstrated some protective effects in female rats but did not protect against GM nephrotoxicity in male rats for unknown reasons, probably related to the effects of sex hormones which needs further studies to be confirmed.
- 1 January 2018
- Published by Medknow in International Journal of Preventive Medicine
- Vol. 9 (1) , 108
Open AccessSex difference in gentamicin-induced nephrotoxicity: Influence of L-arginine in rat model
Background: L-arginine is an important precursor for the formation of nitric oxide (NO). According to previous studies, NO function is related to gender. Likewise, chronic renal diseases have lower prevalence in female. Gentamicin (GM) is an aminoglycoside antibiotic. According to some studies, males are more sensitive to GM renal nephrotoxicity. This study attempts to find protective effects of L-arginine on GM nephrotoxicity in male and female rats. Methods: Male and female rats were divided into eight groups: Rats were randomly assigned to 8 groups each including both male and female rats. The first and second groups received vehicle (saline), the third and fourth groups received gentamicin (80 mg/kg), the fifth and sixth groups received L-arginine (150 mg/kg), and finally, seventh and eighth groups received gentamicin+ L- arginine. Next, 9 days after administering drugs, blood samples were collected from the heart. After making sacrifices, the level of blood urea, creatinine (Cr), nitrite, and malondialdehyde (MDA) was measured in serums. Likewise, nitrite and MDA were measured in the homogenized kidney tissue. Results: GM significantly increased serum level of urea and Cr in male and female rats (P < 0.05). However, co-administration of GM + L-arginine significantly did not decrease urea and Cr level in male rats, whereas, in female rats, they significantly reduced (P < 0.05). In response to GM, renal MDA level increased in male and female rats (P < 0.05), and in the presence of GM + L-arginine, the level of MDA significantly decreased in both genders (P < 0.05). Conclusions: L-arginine demonstrated some protective effects in female rats but did not protect against GM nephrotoxicity in male rats for unknown reasons, probably related to the effects of sex hormones which needs further studies to be confirmed.
- Open Access
- 23 November 2015
- Published by Wiley in Advances in Pharmacological Sciences
- Vol. 2015, 1-7
High-Dose Estradiol-Replacement Therapy Enhances the Renal Vascular Response to Angiotensin II via an AT2-Receptor Dependent Mechanism
Physiological levels of estrogen appear to enhance angiotensin type 2 receptor- (AT2R-) mediated vasodilatation. However, the effects of supraphysiological levels of estrogen, analogous to those achieved with high-dose estrogen replacement therapy in postmenopausal women, remain unknown. Therefore, we pretreated ovariectomized rats with a relatively high dose of estrogen (0.5 mg/kg/week) for two weeks. Subsequently, renal hemodynamic responses to intravenous angiotensin II (Ang II, 30–300 ng/kg/min) were tested under anesthesia, while renal perfusion pressure was held constant. The role of AT2R was examined by pretreating groups of rats with PD123319 or its vehicle. Renal blood flow (RBF) decreased in a dose-related manner in response to Ang II. Responses to Ang II were enhanced by pretreatment with estradiol. For example, at 300 ng kg−1 min−1, Ang II reduced RBF by% in estradiol-treated rats but only by% in vehicle-treated rats. Pretreatment with PD123319 blunted the response of RBF to Ang II in estradiol-treated rats, so that reductions in RBF were similar to those in rats not treated with estradiol. We conclude that supraphysiological levels of estrogen promote AT2R-mediated renal vasoconstriction. This mechanism could potentially contribute to the increased risk of cardiovascular disease associated with hormone replacement therapy using high-dose estrogen.- 23 November 2015
- Published by Wiley in Advances in Pharmacological Sciences
- Vol. 2015, 1-7
Open AccessHigh-Dose Estradiol-Replacement Therapy Enhances the Renal Vascular Response to Angiotensin II via an AT2-Receptor Dependent Mechanism
Physiological levels of estrogen appear to enhance angiotensin type 2 receptor- (AT2R-) mediated vasodilatation. However, the effects of supraphysiological levels of estrogen, analogous to those achieved with high-dose estrogen replacement therapy in postmenopausal women, remain unknown. Therefore, we pretreated ovariectomized rats with a relatively high dose of estrogen (0.5 mg/kg/week) for two weeks. Subsequently, renal hemodynamic responses to intravenous angiotensin II (Ang II, 30–300 ng/kg/min) were tested under anesthesia, while renal perfusion pressure was held constant. The role of AT2R was examined by pretreating groups of rats with PD123319 or its vehicle. Renal blood flow (RBF) decreased in a dose-related manner in response to Ang II. Responses to Ang II were enhanced by pretreatment with estradiol. For example, at 300 ng kg−1 min−1, Ang II reduced RBF by% in estradiol-treated rats but only by% in vehicle-treated rats. Pretreatment with PD123319 blunted the response of RBF to Ang II in estradiol-treated rats, so that reductions in RBF were similar to those in rats not treated with estradiol. We conclude that supraphysiological levels of estrogen promote AT2R-mediated renal vasoconstriction. This mechanism could potentially contribute to the increased risk of cardiovascular disease associated with hormone replacement therapy using high-dose estrogen. - Open Access
- 1 February 2014
- Vol. 5 (2) , 238-240
Role of Angiotensin Type 2 Receptor on Nitric Oxide Production Response to Angiotensin II Administration in Ovariectomised Rats Treated with Estradiol
Background: Renin-angiotensin system activity is gender related. The vasodilatory response of angiotensin II (AngII) angiotensin type 2 receptor (AT2R) may involve nitric oxide (NO) production. We attempted to find the role of AT2R on NO formation response to AngII administration in ovariectomised rats treated with estradiol (OVE). Methods: A total of 33 female Wistar rats were divided into 3 groups; intact animals, ovariectomised treated with placebo (OVX) and OVE. At 2 weeks later, all animals were subjected to anesthetize and catheterize and each group was divided into two subgroups that received AT2R antagonist (PD123319) or vehicle. Each animal was subjected to 1 h continuous infusion of AngII (similar to 20 mu g/kg/h) and the level of NO metabolite (nitrite) was measured before and after AngII infusion. Results: At the presence of AT2R, the serum level of nitrite in response to AngII administration in OVE groups increased significantly (P < 0.05). Conclusions: However, this increase was abolished by AT2R antagonist. It seems that AT2R involves nitrite production response to AngII in OVE.
- 1 February 2014
- Vol. 5 (2) , 238-240
Open AccessRole of Angiotensin Type 2 Receptor on Nitric Oxide Production Response to Angiotensin II Administration in Ovariectomised Rats Treated with Estradiol
Background: Renin-angiotensin system activity is gender related. The vasodilatory response of angiotensin II (AngII) angiotensin type 2 receptor (AT2R) may involve nitric oxide (NO) production. We attempted to find the role of AT2R on NO formation response to AngII administration in ovariectomised rats treated with estradiol (OVE). Methods: A total of 33 female Wistar rats were divided into 3 groups; intact animals, ovariectomised treated with placebo (OVX) and OVE. At 2 weeks later, all animals were subjected to anesthetize and catheterize and each group was divided into two subgroups that received AT2R antagonist (PD123319) or vehicle. Each animal was subjected to 1 h continuous infusion of AngII (similar to 20 mu g/kg/h) and the level of NO metabolite (nitrite) was measured before and after AngII infusion. Results: At the presence of AT2R, the serum level of nitrite in response to AngII administration in OVE groups increased significantly (P < 0.05). Conclusions: However, this increase was abolished by AT2R antagonist. It seems that AT2R involves nitrite production response to AngII in OVE.